18,64 $
0,11 % gestern
Nasdaq, 30. Oktober, 21:02 Uhr
ISIN
US86627R1023
Symbol
SMMT
Berichte

Summit Therapeutics PLC Sponsored ADR Aktie News

Positiv
MarketBeat
2 Tage alt
A company's comeback story can mean a significant opportunity for investors to win returns in the financial world. Of course, when a stock has shed a sizable portion of its value in recent memory, many investors prefer to exercise caution unless there is a clear signal that the firm's fortunes could turn around.
Positiv
24/7 Wall Street
2 Tage alt
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.
Positiv
The Motley Fool
4 Tage alt
Summit Therapeutics' ivonescimab continues to ace phase 3 studies against approved drugs. The investigational cancer medicine could eventually become one of the world's best-selling therapies.
Positiv
24/7 Wall Street
6 Tage alt
While insider buying is typically slower when markets are near all-time highs and when earnings-reporting season is in full swing, it never seems to dry up altogether.
Neutral
The Motley Fool
6 Tage alt
Explore the exciting world of Summit Therapeutics (SMMT +2.83%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
Business Wire
9 Tage alt
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 26.68 million shares of the Company's common stock at $18.74 per share, the closing price on Tuesday, October 21, 2025, for ...
Neutral
Seeking Alpha
10 Tage alt
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2025 Earnings Call October 20, 2025 8:00 AM EDT Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West Mahkam Zanganeh - Co-CEO, President & Director Manmeet Soni - COO, CFO & Director Urte Gayko - Chief Regulatory, Quality & Pharmacovigilance Officer Allen Yang - Chief Medical Officer Robert Duggan - Co-CEO & Executiv...
Negativ
Seeking Alpha
10 Tage alt
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increased trial enrollment and a limited cash runway, with dilution likely if partnerships don't materialize soon. The company's bold BLA strategy and expanded Phase 3 footprint increase binary risk, whi...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen